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Introduction
The 91st Annual Meeting of the American Association for
Cancer Research (AACR) was held at the Moscone Con-
vention Center in San Francisco, California, USA, April
1–5, 2000. The comprehensive and multidisciplinary
nature of the AACR meeting was conveyed through a col-
lection of concurrent symposia, minisymposia and poster
sessions. These standard meeting forums were further
supplemented by additional educational workshops, inter-
active ‘meet-the-expert’ sessions at the beginning of each
day and panel discussions approaching more general
interest topics, such as the relationship of media, science
and consumers. Although it was generally impossible to
attend all of the sessions on a particular topic, many
topics were repeated in different formats throughout the
meeting to allow for attendees to get a reasonable sam-
pling of the current trends in each field.
A number of scientists were honoured at the meeting for
their outstanding contributions to cancer research.
Charles Sherr (St Jude’s Children’s Research Hospital,
Memphis, TN, USA) was awarded the Pezcoller Interna-
tional Cancer Research Award for his work on the mecha-
nisms of cell growth control and neoplastic transformation.
The Bruce F Cain Memorial Award was given to Axel
Ullrich (Max-Planck Institute for Biochemistry, Martinsried,
Germany) who has successfully translated his pioneering
work on tyrosine kinase receptors, such as HER2/neu,
into actual treatment strategies. Edison T Liu (National
Cancer Institute, Bethesda, MD, USA) was also recog-
nized for his work in establishing a correlation between
HER2/neu overexpression and those breast cancers that
have an unfavourable prognosis and high probability of
responding to doxorubicin therapy. Finally, the prestigious
G H A Clowes Memorial Award was presented to Eliza-
beth Blackburn (University of California, San Francisco,
CA, USA) for her pioneering work in the discovery of
telomerase and its potential role in cancer.
Herein we outline a few of the many provocative studies
discussed at the meeting. Although some of the topics dis-
cussed below are specific to the breast, others addressing
global mechanisms of tumour progression are also consid-
ered because they may be appropriate paradigms for
understanding and treating breast cancer in the future.
Steroid and steroid receptor function in breast
cancer progression
The role of steroids and their receptors in breast cancer
progression was the focus of a number of presentations.
In an informative and entertaining plenary session talk,
Malcolm Pike (USC/Norris Comprehensive Cancer
Center, Los Angeles, CA, USA) discussed the concept of
breast cancer prevention through hormonal manipulation
(eg early full-term pregnancy or use of the oral contracep-
tive pill). This theme was followed up in a subsequent mini-
symposium in which a number of animal studies that
examined the timing of oestrogen exposure in breast
cancer risk were presented. Ana Cabanes (Georgetown
University, Washington, DC, USA) showed that prepuber-
tal exposure of rats to oestradiol significantly reduced the
incidence of mammary tumours in 9,10-dimethyl-1,2-benz-
anthracene-treated rats. This could be related to expres-
sion of specific oestrogen receptor (ER) subtypes: in
these rats, ERa appears to be lost temporarily withhttp://breast-cancer-research.com/content/2/4/302
increased expression of ERb. In three related studies from
the laboratory of Satyabrata Nandi (University of California,
Berkeley, CA, USA), short-term hormone treatment
appeared to be effective in mammary cancer prevention in
rodents, which may be due to alterations in mammary
epithelial cell signalling pathways resulting in a reduced
proliferative response during carcinogenesis.
Moving on to steroid receptors, Suzanne Fuqua (Baylor
College of Medicine, Houston, TX, USA) provided an
overview of ERs as targets in breast cancer. This theme
was expanded by Rachel Schiff of the same institute and
recipient of an AACR Susan G Komen Breast Cancer
Foundation Young Investigator Scholar Award, who
described expression of wild-type and variant forms of
ERb in breast tumours using monoclonal and polyclonal
antibodies developed in-house. This is an important devel-
opment because most previous work on ERb has been at
the mRNA level. Analysis of breast tumours revealed
nuclear ERb immunoreactivity, but there were no associa-
tions with known clinical prognostic markers, highlighting
the fact that ERb may have a distinct biological role and is
not just a surrogate for ERa. Cell line work showed a dif-
ferential response to 17b-oestradiol depending on which
ER subtype was expressed, further emphasizing the dis-
tinct biological roles of the a and b receptors. Exon 5-
deleted ERb variants were also detected in cell lines. This
was expanded further by Eli Gilad (Lawrence Berkeley
National Laboratory, Berkeley, CA, USA) who showed that
expression of this variant acts as a dominant-negative
mutant to ERb.
In an eloquent talk by Heather Cunliffe (National Human
Genome Research Institute, Bethesda, MD, USA, and
recipient of an AACR–Ortho Biotech, Inc, Young Investi-
gator Scholar Award), the role of the steroid receptor
coactivator AIB1 was discussed. AIB1 is a receptor coac-
tivator of the p160 family, which is amplified and overex-
pressed in 10% of breast cancers. Using a range of ERa+
cell lines, recruitment of AIB1 into ERa–oestrogen
response element complexes was demonstrated, empha-
sizing the functional significance of this coactivator in
breast tumours with AIB1 amplification.
cDNA array technologies
The rapid evolution of cDNA microarray technology was
evident in a number of oral and poster communications
covering a range of different gene families. There was
tremendous interest in this technology in an educational
session describing the design and analysis of microarray
experiments, as well as its clinical application.
Outi Monni (National Institute of Health, Bethesda, MD,
USA) has applied this approach to characterize the molec-
ular consequences of overexpression of 17q23. Chromo-
some 17 is one of the most frequently amplified genes in
breast cancer, and harbours several cancer-associated
genes, including the tumour suppressor gene p53,
BRCA1 and c-erbB2. An expression survey of gene tran-
scripts revealed amplifications of RAD51C, S6K, PAT1
and TBX2, as well as a novel highly amplified expressed
sequence tag on the 17q23 amplicon. Together with
better-characterized genes, these candidates may con-
tribute to breast cancer development. There were also
examples of coupling this technique with another emerg-
ing technology, laser capture microdissection, which illus-
trates its sensitivity.
In the late-breaking abstract section, John Bartlett (Univer-
sity of Glasgow, Glasgow, UK) described the use of
genomic microarrays to detect copy changes in microdis-
sected breast tumours. In contrast to standard compara-
tive genome hybridization (CGH) protocols, this
‘CGH-on-a-chip’ has the added benefit of defining specific
regions that are reported to be amplified in breast
tumours, and has widespread application in determining
the molecular events that underlie disease progression
and patient outcome.
Clearly, this is a burgeoning area; identification of novel
genes associated with the genesis of breast cancer will
surely lead to a better understanding of the processes
involved, which may have potential for developing novel
treatment strategies in the future.
Microenvironmental contributions to tumour
progression
A growing number of investigators are recognizing that, in
addition to the chromosomal abnormalities and genetic
lesions that destabilize homeostatic cellular function,
tumour progression is largely influenced by the tissue
microenvironment, that is, the matrix and cellular compo-
nents of a given tissue type.
Mina Bissell (Lawrence Berkeley National Laboratory,
Berkeley, CA, USA) described the mammary epithelial cell
models used in her laboratory to understand the mecha-
nisms by which cells normally perceive the surrounding
microenvironment and how, as cells become tumouri-
genic, they lose their ability to sense and respond appro-
priately to cues in the surrounding milieu.
Recent work showed that effective communication
between a cell and its microenvironment is regulated not
only by the coordinate activity of cell-surface receptors,
such as b1 integrin and epidermal growth factor receptor,
but also by changes in nuclear architecture, as was
demonstrated in experiments probing the functional contri-
butions of the nuclear matrix protein NuMA. The impor-
tance of microenvironment in tumour cell metastasis was
addressed by Anne Chambers (London Regional Cancer
Center, London, Ontario, Canada), who discussed aBreast Cancer Research    Vol 2 No 4 Speirs and Schmeichel
unique video microscopy system employed to monitor the
efficiency of tumour metastasis in vivo. Her work shows
that metastasis is a highly inefficient process that is
dependent on the ability of cells to localize to an appropri-
ate growth-promoting environment. Another dramatic
example of the microenvironmental influences on tumouri-
genic behaviour was described in an early morning ‘meet-
the-expert’ session by Gerald Cunha (University of
California, San Francisco, CA, USA), who described
experiments exploring stromal–epithelial cell interactions
in the context of a prostate tumour progression model.
Kidney capsule implants containing mixtures of normal
epithelial cells and carcinoma-derived fibroblasts (but not
normal fibroblasts) gave rise to dramatic tumour growth,
demonstrating that alterations in the stromal constituents
of an epithelial tissue microenvironment can have a pro-
found effect on tumour progression.
Considerable interest was generated from a presentation
by Miaw-Sheue Tsai (Lawrence Berkeley National Labora-
tory, Berkeley, CA, USA) who provided potential new
insights into the mechanisms by which breast tumours
acquire endocrine resistance. By introducing Cyr61, a
ligand for avb3 integrin, into ER+ MCF-7 cells, she demon-
strated loss of oestrogen-dependence, a growth advan-
tage under serum-free conditions and an invasive
outgrowth pattern in Matrigel. Cyr61 may thus be a key
factor in controlling tumour growth and progression,
perhaps via the integrin pathway.
Angiogenesis
Disruption of tumour vasculature is now recognized as a
potentially powerful anticancer strategy. Erkki Ruoslahti
(The Burnham Institute, La Jolla, CA, USA) discussed
how, using a phage display approach, they identified a
series of peptides that home specifically to the microvas-
culature. By coupling these peptides to known toxins they
have developed a strategy for targeting and destroying
newly forming blood vessels in developing tumours. They
have also characterized a prostate-specific homing phage
that targets receptors in normal tissue; normal mice
treated with this prostate-specific phage experience exten-
sive cellular apoptosis in the gland and an overall reduc-
tion in prostate size. Thus, this strategy might be a viable
alternative to surgical intervention in patients diagnosed
with hypertrophic prostate glands.
The strong antiangiogenic properties of endostatin make
this an attractive candidate for antiangiogenic therapy, but
its short half-life makes its effective delivery difficult. To
overcome this, an encapsulated polymer system was
described by Tatsuhiro Joki (Harvard Medical School,
Boston, MA, USA) as a potentially new way of delivering
bioactive endostatin. BHK cells were transfected with an
endostatin expression vector, and clones expressing high
levels of the protein were selected. These were encapsu-
lated in an alginate–polylysine matrix and biologically
active endostatin (ie that retained its ability to inhibit angio-
genesis) was produced for up to 4 weeks. The use of
encapsulated local delivery systems could provide a
promising therapeutic approach not only for endostatin,
but for other anticancer agents as well.
Groups from the UK and Japan discussed two new
angiogenesis inhibitors with clinical potential. Preliminary
in vitro data with the tubulin-binding agent ZD6126
(ANG 453) showed selective damage to tumour vascula-
ture and widespread necrosis in a range of tumour
xenografts, whereas ER-68203-00 also had potent
antiangiogenic effects. The broad-spectrum angiogene-
sis inhibitor, SU6668, which is currently in phase 1 clini-
cal trials, was shown by Douglas Laird (Sugen, San
Francisco, CA, USA) to have growth inhibitory effects
against a range of newly implanted and established
xenografts of different tumour types. As SU6668 inhibits
signalling from the vascular endothelial growth factor,
fibroblast growth factor and platelet-derived growth
factor receptors, its inhibitory effects probably impact
both on paracrine and on autocrine pathways, likely
involving multiple cell types. In a provocative and contro-
versial talk, Mary Hendrix (University of Iowa College of
Medicine, Iowa City, IA, USA) described studies that
demonstrated that tumour cells derived from uveal
melanomas have the capacity to form blood-bearing
channels that are distinct in morphology and behaviour
from canonical endothelial-lined angiogenic vessels. In
addition to elucidating a potentially novel mechanism of
tumour-dependent angiogenesis, these studies provide
an excellent example of how even tumour cells, in
response to cues from the tissue microenvironment, can
adopt an altered phenotype in vivo, perhaps masquerad-
ing as endothelial cells.
Other molecular targeting strategies
A number of additional targeting strategies were pre-
sented at this meeting, some of which may not only
increase the efficacy of drug delivery, but may also facili-
tate drug intervention at localized sites in the body.
Ellen Vittetta (UT Southwestern Medical Center, Dallas,
TX, USA) discussed the status of targeted antibody thera-
pies, including the potential for increased efficacy of
cross-linked antibodies. For example, recent studies in her
laboratory have shown that treatment of lymphoma cells
with covalently cross-linked P-glycoprotein antibodies sig-
nificantly enhances toxic effects of the chemotherapeutic
agent doxorubicin. Dr Vitetta also described improved
strategies for mouse/human chimeric antibody design by
genetic engineering and predicted that future advances
will probably involve the development of antibody mimetic
molecules that have increased therapeutic efficacy in com-
parison to the traditional antibody approaches of today.Bioavailability was also the concern of Stephen Dowdy
(Washington University, St Louis, MO, USA) who
described a molecular delivery system based on an
11-amino-acid sequence, derived from the HIV Tat
protein, which is sufficient to mediate protein transduction
in a receptor-independent manner across cell membranes.
When injected into mice, purified Tat-tagged-recombinant
proteins (ie Tat–LacZ fusions) can be detected in solid
tissues, tumours and in blood cells in less than an hour.
Based on the success of these proof-of-principle studies,
the Tat-dependent transduction system is now being
developed for the delivery of tumour suppressor proteins,
such as p53 and PTEN, and chemotherapeutic agents,
such as doxorubicin, to tumour tissues.
The use of Tat-coupled DNA molecules may even be a
viable approach for gene therapy. Roland Burli (California
Institute of Technology, Pasadena, CA, USA) outlined the
design and use of membrane-permeant gene-specific
DNA-binding ligands to attenuate expression of cancer-
promoting oncogenes such as HER2/neu.
Finally, work from the group of Brian Druker (Oregon
Health Sciences University, Portland, OR, USA) described
the development of a small molecule inhibitor, STI571, in
treating patients diagnosed with chronic myeloid
leukaemia, a disease in which 95% of patients express a
constitutively activated Bcr-Abl tyrosine kinase. STI571
shows potent inhibitory activity against the Bcr-Abl kinase
in vitro, and phase 1 clinical trials show complete haema-
tological responses to STI571 treatment with no
detectable toxicity in patients heavily pretreated with con-
ventional therapies. ST1571 will now be tested in treat-
ment naïve patients in combination with the standard
no-tumour selective approaches. The dramatic efficacy
observed in toxicity (phase 1) studies portend that this
small molecule kinase inhibitor will become part of stan-
dard care in this disease.
Epigenetics and cancer
Clearly, genetic mutation is a fundamental mechanism by
which gene expression and function are altered, thereby
giving rise to aberrant or cancerous behaviour in cells and
tissues. However, many are now discovering that muta-
tion-independent, epigenetic mechanisms, including DNA
methylation and histone acetylation, are also critical
determinants of tumour progression when they are aber-
rantly regulated.
Adrian Bird (University of Edinburgh, Edinburgh, UK) gave
an overview talk on the role of DNA methylation and
histone acetylation status in gene silencing. It now
appears that a variety of tumour suppressor genes, includ-
ing those that encode E-cadherin, VHL and hMLH1, are
inactivated in cancer not by canonical gene mutation, but
rather by methylation-dependent promoter silencing.
Because promoter hypermethylation is potentially
reversible, the molecules that regulate methylation status
of DNA are considered promising targets for new cancer
therapies. As a proof of this principle, Paula Vertino
(Emory University, Atlanta, GA, USA) described the identi-
fication and characterization of TMS-1, a gene that is
hypermethylated in a variety of breast carcinoma cell lines
and primary tumours. Treatment of the cell lines with the
methyl transferase inhibitor 5azaC reverses the methyla-
tion pattern of TMS-1 and restores expression of the
TMS-1 molecule.
Joseph Costello (University of California at San Francisco
Cancer Center, San Francisco, CA, USA) has used an
alternative strategy in developing a broad-based screen to
identify candidate CpG islands and to examine differential
methylation at these sites between nonmalignant and
tumour tissues. Not only is this approach useful for the
identification of new epigenetically regulated genes, but
this type of analysis may also be applicable for diagnostic
purposes, because the observed patterns may be indica-
tive of particular tumour types.
The protein components that control methylation and
histone deacetylation were explored in depth in another
symposium entitled ‘The Cancer–Chromatin Connection’.
Using the transcriptionally repressed gene, MDR1, as a
model, Alan Wolffe (National Institute of Health, Bethesda,
MD, USA) presented studies that illustrate the intimate
relationship between histone acetylation and DNA methy-
lation in the control of gene expression. Although treat-
ment of cells with either the demethylation inhibitor
5-azacytidine, or the histone deacetylase inhibitor tricho-
statin A was not sufficient to reactivate MDR1 expression,
a cocktail of both inhibitors acts synergistically to dramati-
cally induce MDR1 transcription. Reinduction of MDR1
gene expression is accompanied by a reduction in the
methyl CpG binding protein MeCP2, and by the reduced
acetylation of histones.
The complexity and significance of chromatin remodelling in
controlling cellular behaviour was further illustrated by
Douglas Dean (Washington University School of Medicine,
St Louis, MO, USA), who showed that unphosphorylated
Rb forms transcriptional repression complexes with histone
deacetylase and the nucleosome remodelling unit
SWI/SNF, or alternatively with just SWI/SNF. Each of these
complexes control distinct checkpoints at G1- and S-phase
by regulating the ordered of expression of the cyclins that
ultimately drive the progression of the cell cycle.
Conclusion
Overall, this was an excellent meeting, covering a variety
of aspects of clinical and laboratory breast cancer
research. We have provided an overview of what we
believe to be the most significant contributions. For those
http://breast-cancer-research.com/content/2/4/302who wish to obtain further details, abstracts are available
on-line via the AACR web page (www.aacr.org/). The next
annual AACR meeting will be held during March 24–28,
2001, New Orleans, LA, USA.
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